RANI
Rani Therapeutics Holdings, Inc.1.4400
-0.0100-0.69%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
176.61MP/E (TTM)
-Basic EPS (TTM)
-0.77Dividend Yield
0%Recent Filings
10-K
FY2025 results
Rani Therapeutics reported FY2025 ended December 31, 2025 with no approved products and no historical commercial product revenue, sustaining operating losses as an early clinical-stage biopharma. Q4 momentum built via October's $10.0 million Chugai upfront for RaniPill HC hemophilia collaboration and $60.3 million private placement, plus debt extinguishment leaving zero obligations. December initiated Phase 1 RT-114 obesity trial using RaniPill HC. No debt weighs liquidity positively. Clinical trial delays threaten quarterly progress.
8-K
Q4 loss shrinks, cash jumps
Rani Therapeutics reported Q4 and full-year 2025 results, slashing net loss to $9.1M from $15.7M while cash swelled to $49.7M, funding ops into Q4 2027. Key wins: $1.085B Chugai collaboration for oral rare disease therapy and $60.3M private placement; debt fully cleared. Phase 1 RT-114 obesity trial kicked off. Cash fuels clinical push.
8-K
TRA terminated, voting equalized
Rani Therapeutics terminated its 2021 Tax Receivable Agreement with InCube Labs on December 31, 2025, eliminating all future obligations without payments. It filed a Restated Charter slashing Class B voting power from 10 to 1 vote per share, banning written consents, and adding stockholder protections. Governance simplified. Majority holder approved via November consent.
8-K
Chugai deal, $60M raise
Rani Therapeutics sealed a collaboration with Chugai worth up to $1.085B for oral rare disease therapies via RaniPill, paired with a $60.3M oversubscribed private placement from Samsara BioCapital and others that converted $6M debt. Cash extends into 2028. Board adds Bassan and Bailey. Q3 net loss shrank to $7.9M from $12.7M.
10-Q
Q3 FY2025 results
Rani Therapeutics narrowed Q3 operating losses to $7.3M from $11.8M y/y (derived), trimming R&D 48% to $3.2M and G&A 28% to $4.0M via headcount cuts and paused programs. YTD net loss attributable to Rani Holdings improved to $19.4M ($0.50/share) from $21.1M ($0.78/share) y/y on $172K contract revenue; EPS aligns with 38.9M diluted shares. Cash dipped to $4.1M amid $19.0M YTD operating burn, yet $13.5M debt matures soon (14.6% rate). Post-quarter, closed $60.3M private placement (converting $6M debt), $10M Chugai upfront for hemophilia oral collab, and $4.5M warrant exercises—alleviating going concern doubt. Nasdaq relisting risks loom if equity volatility persists.
IPO
Employees
Sector
Industry
ENTX
Entera Bio Ltd.
2.09+0.01
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
PPCB
Propanc Biopharma, Inc.
0.73-0.03
RADX
Radiopharm Theranostics Limited
5.99-4.64
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
RLMD
Relmada Therapeutics, Inc.
4.50+0.14
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
TARA
Protara Therapeutics, Inc.
5.42-0.08
VANI
Vivani Medical, Inc.
1.41+0.06
VKTX
Viking Therapeutics, Inc.
35.72-0.43